Clinical Trial Update: A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetic study of ABT-199 (venetoclax) in adults with non-Hodgkin's lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Venetoclax (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Relapsed/Refractory Non-Hodgkin's Lymphoma | Phase 1 | Status: WITHDRAWN